Ibotta stock rating downgraded by Evercore ISI after Q2 miss

Ibotta Inc. (IBTA) reported disappointing second-quarter results, with revenue declining 2% year-over-year and missing Street expectations, alongside an EBITDA miss. The company also issued significantly weaker-than-expected third-quarter guidance, citing disruptions from sales reorganization, slower client scaling, and product delays. This performance and outlook led Evercore ISI to downgrade IBTA to In Line and slash its price target to $38, while Citizens JMP also downgraded the stock, reflecting significant operational challenges and a deteriorating near-term outlook for the digital rewards platform.

Analysis

Ibotta Inc. (IBTA) is facing significant operational headwinds, evidenced by its disappointing second-quarter results and a sharply negative outlook for the third quarter. The company reported a 2% year-over-year revenue decline to $86 million, missing analyst expectations by 5%, while its EBITDA of $17.9 million fell 12% short of consensus. Management attributed the poor performance to internal disruptions, specifically a sales reorganization and delays in scaling new clients. The forward-looking guidance is more concerning, with a Q3 revenue forecast of $79-$84 million, representing a steep 17% year-over-year decline at the midpoint. This deteriorating top-line trajectory, coupled with EBITDA guidance also well below Street estimates, triggered two notable analyst downgrades. Evercore ISI cut its rating to In Line and slashed its price target by nearly 42% to $38.00, while Citizens JMP moved to Market Perform, citing product delays and limited revenue visibility. Despite these challenges, the company's fundamental model retains a key strength with gross profit margins remaining high at nearly 85%, though this is overshadowed by the current revenue and execution issues that have contributed to a 54% stock price decline over the past six months.

Key Decisions for Investors

• Given the significant Q3 guidance miss projecting a 17% year-over-year revenue decline and multiple analyst downgrades, investors should exercise caution as the stock's fundamental outlook has materially weakened.
• Monitor management's execution on its sales reorganization and product development roadmap, as progress or further setbacks in these areas will be critical catalysts for the stock's performance.
• While the stock has fallen over 50% in six months, the lack of revenue visibility and ongoing operational issues suggest that a re-evaluation of valuation is necessary before considering the current price an attractive entry point.